Skip to main content
. 2023 May 24;14:1172199. doi: 10.3389/fendo.2023.1172199

Table 3.

Effect of mPTD-BMP7 assessed by clinical parameters in the animal models of diabetes.

Control
(n=5)
STZ + Vehicle
(n=7)
STZ + mPTD-BMP7
(n=6)
Body weight (g) 28.97 ± 0.63 21.09 ± 1.24 21.57 ± 2.26
Kidney weight (mg) 155.45 ± 17.56 185.69 ± 16.18 179.09 ± 29.60
Kidney/body weight (mg/g) 5.37 ± 0.66 8.80 ± 0.39 8.36 ± 1.39
Blood glucose (mg/dL) 181.20 ± 61.21 489.57 ± 144.00 437.17 ± 124.69
HbA1c (%) 5.92 ± 0.96 10.83 ± 1.43 9.60 ± 2.52
Serum bilirubin (mg/dL) 0.03 ± 0.02 0.07 ± 0.03* 0.04 ± 0.02#
Serum Creatinine (mg/dL) 0.18 ± 0.05 0.18 ± 0.05 0.13 ± 0.04
Serum BUN (mg/dL) 25.60 ± 5.37 36.43 ± 9.22 42.83 ± 17.02
Urine Creatinine (mg/dL) 50.42 ± 12.64 6.37 ± 0.47 10.46 ± 11.95
24-hr Urine Albumin (μg) 6.60 ± 2.73 49.99 ± 23.74 39.47 ± 26.10
UACR (μg/mg) 16.05 ± 8.47 37.06 ± 10.79* 31.60 ± 18.27#

STZ, streptozotocin; mPTD-BMP7, protein transduction domain-fused BMP7 in micelle; BUN, blood urea nitrogen; UACR, urine albumin-creatinine ratio. *P < 0.05; versus control group. #P < 0.05; versus STZ + Vehicle group.